Advancing mitochondrial medicine
About Santhera

About


Santhera


We are a Swiss specialty pharmaceutical company committed to developing medicines to meet the needs of patients living with mitochondrial disorders and other rare diseases.
________

Read more >>

PATIENTS


About mitochondrial diseases


At Santhera, we are passionate about providing treatment options for patients with rare mitochondrial diseases, specifically in the area of neuromuscular and neuro-ophthalmological conditions – diseases that have a severe impact on the lives of affected children and adults.
________

Read more >>
home-picture-01
Our medicines

Health Care Professionals


Our medicines



Our focus is on the development of treatments for neuromuscular and neuro-ophthalmological diseases that currently lack treatment options. In September 2015, we received our first European Marketing Authorization for Raxone® in the treatment of patients with Leber’s hereditary optic neuropathy.

________

Read more >>

Investors & Media


Tools and Resources



The Investor and Media center provides information and resources for investor and media communities.

________

Read more >>
Tools and Resources
Working at Santhera

Career


Working @Santhera



Santhera is a dynamic and international employer looking for colleagues who are talented, engaged and committed to growing the organization through the work that they do.

________

Read more >>

Join our Feeds

news

Latest News

May 20, 2016
Santhera receives FDA Fast Track Designation for Omigapil for the Treatment of Congenital Muscular Dystrophies (CMD)
Read morepdf-icon


May 11, 2016
Santhera’s Shareholders Approve all Board Proposals at Annual Shareholders’ Meeting
Read morepdf-icon


May 11, 2016
Annual General Shareholder Meeting.
10.30 am, MCH Messe Schweiz (Basel) AG, 4005 Basel, Switzerland.
Read morepdf-icon


May 3, 2016
Santhera Updates on Regulatory Filings for Raxone® (idebenone) in Duchenne Muscular Dystrophy (DMD)
Read morepdf-icon


April 14, 2016
Santhera Co-Sponsors and Presents at the First "Duchenne Pulmonary Outcomes Workshop" Organized by Parent Project Muscular Dystrophy (PPMD)
Read morepdf-icon


April 12, 2016
Santhera Reports Increase in Product Sales, Positive Net Result for 2015 and Progress in All Programs 
Read morepdf-icon


To subscribe to our News Feed, please click here.

facebook

Facebook

linkedin

Linked In

This section of the website is intended to provide healthcare professionals with information about Raxone® and other products in Santhera’s pipeline. I am a healthcare professional I am not a healthcare professional